Fennec Provides Business Update and Announces Fiscal Year 2019 Financial Results

NEXT STORY
New Study Demonstrates the Ability of Prolaris® to Predict Which Men With Prostate Cancer Will Benefit from Multi-Modality Therapy
PREV STORY
Verona Pharma Announces Publication of Key Phase 2b COPD Data in Respiratory Research
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Victoza® significantly reduces the risk of major adverse cardiovascular events in the LEADER trial

Bagsværd, Denmark, 4 March 2016 - Novo Nordisk today announced the top-line results from ...

author_avatar
NASDAQ Market News

Advaxis Announces Agreement with Columbia University Irving Medical Center to Fund Phase 1 Study of ADXS-504 for the Treatment of Early Prostate Cancer

author_avatar
NASDAQ Market News

CohBar Confirms Efficacy of Novel Apelin Agonists in Acute Respiratory Distress Syndrome (ARDS) Model

author_avatar
NASDAQ Market News